AR and prostate carcinoma: As well as such developmental studies, future uses of this model include evaluation and detection androgenic xenobiotics and selective androgen receptor modulators (SARMs) with the aim of producing tissue-selective antagonistic or agonistic effects in diseases such as breast and prostate cancer, polycystic ovarian syndrome and hyper- and hypogonadism [64].